Ex vivo treatment of malignant pleural effusions with the bispecific antibody MT110 targeting EPCAM and CD3

被引：0
|
作者：
Witthauer, J. [1 ,2 ]
Schlereth, B. [2 ]
Brischwein, K. [2 ]
Jauch, K. -W. [1 ]
Mayer, B. [1 ]
机构：
[1] Univ Munich, LMU, Dept Surg, Munich, Germany
[2] Micromet AG, Munich, Germany
来源：
ONKOLOGIE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [41] TARGETING LEUKEMIC STEM CELLS IN AML USING THE BISPECIFIC CD33/CD3 BITE® ANTIBODY AMG 330
    Krupka, C.
    Kufer, P.
    Kischel, R.
    Koehnke, T.
    Zugmaier, G.
    Baeuerle, P.
    Vick, B.
    Konstandin, N.
    Jeremias, I.
    Spiekermann, K.
    Riethmueller, G.
    Hiddemann, W.
    Subklewe, M.
    HAEMATOLOGICA, 2014, 99 : 526 - 526
  • [42] Targeting leukemic stem cells in AML using the Bispecific CD33/CD3 BiTE® antibody AMG 330
    Krupka, C.
    Koehnke, T.
    Lichtenegger, F.
    Altmann, T.
    Vick, B.
    Konstandin, N.
    Metzeler, K.
    Jeremias, I
    Spiekermann, K.
    Riethmueller, G.
    Hiddemann, W.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 114 - 114
  • [43] Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
    Luo, Meiying
    Wang, Xiaohuan
    Yu, Guoji
    Ji, Jing
    Li, Long
    Song, Fan
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [44] CD19/CD3 bispecific antibodies induce potent response against chronic lymphocytic leukemia cells ex vivo
    Robinson, Hannah Ruth
    Qi, Junpeng
    Baskar, Sivasubramanian
    Rader, Christoph
    Wiestner, Adrian
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [45] Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia
    Durben, Michael
    Schmiedel, Dominik
    Hofmann, Martin
    Vogt, Fabian
    Nuebling, Tina
    Pyz, Elwira
    Buehring, Hans-Joerg
    Rammensee, Hans-Georg
    Salih, Helmut R.
    Grosse-Hovest, Ludger
    Jung, Gundram
    MOLECULAR THERAPY, 2015, 23 (04) : 648 - 655
  • [46] Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hibreast cancer via enhancing immune cells activity
    Hong, Ri
    Zhou, Yuhai
    Tian, Xiujuan
    Wang, Lijuan
    Wu, Xiaoyun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 54 : 118 - 124
  • [47] A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma
    Xiong, Mengshang
    Liu, Ruoqi
    Lei, Xiaomin
    Fan, Dongmei
    Lin, Fangzhen
    Hao, Wei
    Yuan, Xiangfei
    Yang, Yuanyuan
    Zhang, Xiaolong
    Ye, Zhou
    Lu, Yang
    Zhang, Yanjun
    Wang, Jianxiang
    Xiong, Dongsheng
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (02) : 78 - 88
  • [48] Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
    Ferrari, Francesca
    Bellone, Stefania
    Black, Jonathan
    Schwab, Carlton L.
    Lopez, Salvatore
    Cocco, Emiliano
    Bonazzoli, Elena
    Predolini, Federica
    Menderes, Gulden
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
  • [49] An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers
    Diana, O.
    Chow, Kronos
    Iyer, Deepak
    Wong, Monarca
    Wong, Tony K.
    Wong, Dennis A.
    Luk, John Moon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
    Francesca Ferrari
    Stefania Bellone
    Jonathan Black
    Carlton L. Schwab
    Salvatore Lopez
    Emiliano Cocco
    Elena Bonazzoli
    Federica Predolini
    Gulden Menderes
    Babak Litkouhi
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E. Schwartz
    Alessandro D. Santin
    Journal of Experimental & Clinical Cancer Research, 34
12345